Dianthus Therapeutics, Inc.
NASDAQ:DNTH · NASDAQ Capital Market
-$1.03 today
Vol 2.48M · Avg 0.82M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-32.9%
avg -45.0%
ROIC
-35.5%
avg -46.2%
ROA
-30.6%
avg -39.8%
Analysis
ROA is currently the strongest return metric at -30.6% versus its period average of -39.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Marino Garcia | President, Chief Executive Officer & Director | $1.16M | — | 60 | $269,408.00 | 0.65% |
Simrat Randhawa | Executive Vice President and Head of R&D | $932,680.00 | — | 56 | $64,276.00 | 0.15% |
Ryan Savitz | Executive VP, CFO, Chief Business Officer & Treasurer | $786,096.00 | — | 37 | $71,776.00 | 0.17% |
Adam Veness | Senior Vice President, General Counsel & Secretary | — | — | 40 | $100,000.00 | 0.24% |
Edward G. Carr | Senior VP & Chief Accounting Officer | — | — | 57 | $63,818.00 | 0.15% |
Judson Taylor | Senior Vice President & Head of Technical Operations | — | — | — | — | — |
Jennifer Davis Ruff | Vice President and Head of Investor Relations & Corporate Affairs. | — | — | — | — | — |
Rashieda Gluck | Head of Clinical Development Operations | — | — | — | — | — |
Kristina Maximenko | Chief People Officer | — | — | — | — | — |
Scott Nogi | Head of Business Operations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
32
$40.20M
Net Sentiment
$40.20M
Net selling
Most Active
Savitz Ryan
11 transactions
1–10 of 32
Analysis
Insiders reported 0 buys worth $0.00 and 32 sells worth $40.20M over the last 12 months. That adds up to net selling of $40.20M. Savitz Ryan was the most active insider with 11 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | N/A5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Enliven Therapeutics, Inc.
NASDAQ:ELVN
$2.75B
AnaptysBio, Inc.
NASDAQ:ANAB
$2.42B
Taysha Gene Therapies, Inc.
NASDAQ:TSHA
$1.81B
Atai Beckley Inc.
NASDAQ:ATAI
$1.49B
Immatics N.V.
NASDAQ:IMTX
$1.31B
Tourmaline Bio, Inc.
TRML
$1.23B
Nektar Therapeutics
NASDAQ:NKTR
$1.18B
Sana Biotechnology, Inc.
NASDAQ:SANA
$857.14M
Oculis Holding AG
NASDAQ:OCS
$642.87M
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
$608.81M
Who manages DNTH?
Dianthus Therapeutics, Inc. (DNTH) lists 10 active executives. The top listed executive is Adam Veness, Senior Vice President, General Counsel & Secretary.
Are DNTH insiders buying or selling?
Recent insider activity shows net buying of $94.50M.
Explore More
Continue the stock analysis
Jump to another research area for this company.